11:45 AM EDT, 03/13/2026 (MT Newswires) -- Profound Medical ( PROF ) said Friday that a trial of its MRI-guided Tulsa procedure met the primary safety endpoint, showing better preservation of erectile function and urinary continence than robotic radical prostatectomy in men with localized prostate cancer.

The trial, in which 211 patients were treated, showed 50% preserved both erectile function and urinary continence at 6 months after Tulsa therapy compared with 24% after radical prostatectomy.

Profound Medical ( PROF ) shares were 0.9% lower in Friday trading.

Price: 5.61, Change: +0.06, Percent Change: +1.08